Daniel Oday: Last News

+1

All news where Daniel Oday is mentioned

23.12 / 04:51
News Treatment Twice-Yearly HIV Treatment Approved for Those With Drug Resistance
The U.S. Food and Drug Administration approved the drug Sunlenca (lenacapavir), produced by Gilead Sciences, in combination with other antiretrovirals for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection.Sunlenca offers a new, twice-yearly treatment option for HIV-positive adults that is not adequately controlled by their current regimen.“Today’s approval ushers in a new class of antiretroviral drugs that may help patients with HIV who have run out of treatment options,” Debra Birnkrant, M.D., said in a press release from the FDA.
DMCA